Actively Recruiting
Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)
Led by Jonathan Troy Grennan · Updated on 2024-08-05
560
Participants Needed
6
Research Sites
212 weeks
Total Duration
On this page
Sponsors
J
Jonathan Troy Grennan
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
There is a growing epidemic of the bacterial sexually transmitted infections (STIs) syphilis, chlamydia and gonorrhea worldwide; similarly concerning trends have been noted in Canada, where increases of over 160% have been seen in bacterial STIs over the last decade. In Canada, gay, bisexual, and other men who have sex with men (gbMSM) - including those living with HIV - are disproportionately impacted by bacterial STIs5,6These dramatic increases in bacterial STIs, the potential development of serious complications including AMR, and waning effectiveness of the promotion of conventional STI prevention tools (e.g. condoms), signals the need for novel STI prevention strategies and tools to mitigate STI-related complications. A rigorous randomized controlled trial will be conducted to compare STI PrEP vs. STI PEP and definitively assess the efficacy, safety, antimicrobial resistance profiles and costs associated with doxycycline-based STI prevention.
CONDITIONS
Official Title
Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and 18 years of age or older
- Had sexual activity with more than one male partner in the past 12 months
- Intend to remain sexually active with more than one male partner in the next 12 months
- At least one prior episode of diagnosed and treated syphilis, gonorrhea, or chlamydia within 12 months before screening
You will not qualify if you...
- Allergy to doxycycline or tetracycline antibiotics
- Current or chronic use of tetracycline or doxycycline (e.g. for osteomyelitis or acne)
- Use of medications that reduce doxycycline levels, including barbiturates, phenytoin, and carbamazepine
- Current use of isotretinoin
- Individuals who can become pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Sheldon Chumir Centre
Calgary, Alberta, Canada
Actively Recruiting
2
BC Centre for Disease Control
Vancouver, British Columbia, Canada, V5Z4R4
Actively Recruiting
3
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Not Yet Recruiting
4
The Ottawa Hospital
Ottawa, Ontario, Canada
Not Yet Recruiting
5
St. Michael's Hospital
Toronto, Ontario, Canada
Actively Recruiting
6
McGill University Health Centre
Montreal, Quebec, Canada
Actively Recruiting
Research Team
S
Saira Mohammed
CONTACT
T
Troy Grennan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here